Investor Day 2024
Logotype for Centene Corporation

Centene (CNC) Investor Day 2024 summary

Event summary combining transcript, slides, and related documents.

Logotype for Centene Corporation

Investor Day 2024 summary

8 Jul, 2026

Strategic direction and growth opportunities

  • 2025 adjusted EPS guidance is set above $7.25, representing over 6% year-over-year growth, with a long-term EPS CAGR target of 12%-15%.

  • Focus is on three core businesses—Medicaid, Medicare, and Marketplace—while highlighting disruptive growth in Duals alignment and ICHRA.

  • Medicaid remains the core, with presence in 30 states and 2,098 counties, and ongoing growth in managed care and complex populations.

  • Marketplace leadership is reinforced by 4.5 million members and over $30 billion in projected 2025 revenue, with a sustainable pre-tax margin target of 5%-7.5%.

  • ICHRA market entry is underway, with new plans launched in six states and partnerships to access over 500,000 employer groups.

Financial guidance and embedded earnings

  • 2025 premium and service revenue guidance is $154.0–$156.0 billion, up from $143.5–$144.5 billion in 2024.

  • Medicaid expected to represent 55% of 2025 revenue, with a 3%-4% average net rate increase and ongoing rate recapture efforts.

  • Medicare segment targets break-even by 2027, with margin improvement driven by SG&A reductions and operational efficiencies.

  • PDP business projected at $14.5 billion in 2025 revenue, with a path to increase pre-tax margins from 1% to at least 3%.

  • Embedded earnings power identified in Medicaid margin normalization, Medicare turnaround, and PDP margin expansion, with scenario planning for potential eAPTC subsidy changes.

Policy and market environment

  • Political landscape remains divided but bipartisan support for Medicaid and Marketplace stability is strong, with enhanced APTCs likely to see some form of extension.

  • Ten states have not expanded Medicaid, representing a $2.65B opportunity if expansion occurs.

  • Medicare Advantage outlook includes more favorable rates and Star ratings, with a focus on duals integration and drug pricing innovation.

  • Marketplace growth is supported by eAPTCs, with contingency plans for subsidy expiration, including dual rate filings and pricing adjustments.

  • M&A remains a strategic option, with a focus on core business expansion and capabilities that accelerate disruptive opportunities.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more